Latest Director Appointments News

DMC Mining Limited moves closer to ASX re-admission as Guinea reopens its cadastral licensing system, enabling imminent exploration licenses for key projects. The company also strengthens its leadership team and secures additional financing to support upcoming operations.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

Dubber Corporation Limited reports steady revenue growth and cost reductions in Q2 FY25, alongside a refreshed board and strategic initiatives aimed at achieving operating cashflow breakeven by year-end.

Sunshine Metals Ltd reports a substantial upgrade to its Ravenswood Consolidated Project, with a 57% rise in contained gold and positive drilling and metallurgical results underpinning the growth.

Clara Resources outlines key progress on its Ashford Coking Coal Project drilling preparations and details ongoing capital management initiatives, including rights issues and entitlement offers, while navigating boardroom challenges.

Identitii reports solid quarterly progress highlighted by a strategic new director appointment, US market expansion, and a successful $1.8 million capital raise, underpinning its path toward profitability.

Lindian Resources has secured a US$50 million non-binding funding term sheet with Gerald Group, progressing its Kangankunde Rare Earths Project, while also signing a 10-year lease for its Woula bauxite project in Guinea and navigating significant board changes.

Raiz Invest Limited reports robust growth in Q2 FY25 with active customers rising 8.5% year-on-year and funds under management surging 32.4%, underpinned by product innovation and strong net inflows.

I Synergy Group Limited has reshaped its board with the resignation of Joshua Hunt, the appointment of Jiayi Yu as Non-Executive Director, and the promotion of Heng Jee Meng to Managing Director, signaling a renewed focus on shareholder value.

SomnoMed reports a robust 19.8% revenue increase in Q2 FY25 and updates its full-year guidance, reflecting strong demand and operational improvements amid ongoing production enhancements.